3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
5
Terminated
1
Suspended
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
215
Gastrointestinal
58
Breast
53
Thoracic
45
Genitourinary
41
Head & Neck
24
Dermatologic
23
Sarcoma
14
Other solid neoplasm
8
Lymphoid
6
Other hematologic neoplasm
5
CNS
5
Plasma cell
3
Endocrine
2
NET
1
Classical hematology
1
Conditions
Neuroendocrine Tumors
51
Gastro-enteropancreatic neuroendocrine tumor
10
Carcinoma, Neuroendocrine
8
Small Cell Lung Carcinoma
6
Adenoma, Islet Cell
6
Colorectal Neoplasms
4
Cholangiocarcinoma
3
Carcinoma, Merkel Cell
3
Carcinoma, Hepatocellular
3
Carcinoid Tumor
3
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Salivary Gland Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Pancreatic Neoplasms
2
Neoplasms, Unknown Primary
2
Neoplasms
2
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Medullary
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Vulvar Neoplasms
1
Vipoma
1
Urinary Bladder Neoplasms
1
Thyroid cancer, medullary
1
Thyroid Cancer, Papillary
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Interventions
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Ovarian Neoplasms
×
NET
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA